Meanwhile, women with ER−/PGR+ or ER-poor/PGR− tumours also receive adjuvant anti-oestrogen hormone therapy with hope that this treatment will benefit this group of patients [27, 28]. This evidence concerns the gene ESR1 and neoplasm.